对外部光束辐射与肝细胞癌跨动脉化学栓塞的随机对照试验的元分析
Ryan A Kuehnle1, Leila T Tchelebi2, Ethan B Ludmir3
1Long School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
Cancer
|January 31, 2025
概括
与跨动脉化学栓塞 (TACE) 相比,外部束辐射疗法 (EBRT) 改善了肝细胞癌 (HCC) 的局部控制和无进展生存率. 然而,这两种治疗方法的生存益处并没有显著不同.
科学领域:
- 在瘤学瘤学.
- 辐射瘤学 辐射瘤学
- 肝病学 肝病学是一种肝病学.
背景情况:
- 外部光束辐射疗法 (EBRT) 为肝细胞癌 (HCC) 提供了一种非侵入性治疗选择.
- 在HCC管理中,EBRT是跨动脉化学栓塞 (TACE) 的替代方案.
- 这项研究的重点是比较这两种治疗方法.
研究的目的:
- 系统地审查和元分析潜在的随机临床试验.
- 评估EBRT与TACE对HCC的临床疗效.
- 评估作为最终单一疗法或作为移植/手术的桥梁的治疗方法.
主要方法:
- 对前性随机试验进行系统审查和元分析,比较EBRT和TACE.
- 使用随机和固定效应模型进行分析,评估与I2的异质性.
- 包括与142名患者进行的三项试验,分析了局部控制,整体存活率,无进展存活率和毒性.
主要成果:
- 与TACE相比,EBRT显著改善了局部控制 (HR,0.16) 和无进展生存率 (HR,0.37).
- 没有观察到总生存时间 (RR,0.79) 或毒性等级≥3 (RR,0.86) 的显著差异.
- 所有分析都显示了较低的统计异质性 (LC,PFS,OS I2=0%,毒性 I2=57%).
结论:
- 与TACE相比,EBRT为早期和中间阶段的HCC提供了优越的局部控制和无进展生存.
- 在这些患者群体中,EBRT与TACE相比没有显著的生存益处.
- 建议进行更大规模的前性试验,以探索高级HCC的结果.
更多相关视频
09:49Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
Published on: December 2, 2013
10.3K
09:11Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
396
相关概念视频
Hazard Ratio
96
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
96
Cancer Survival Analysis
334
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
334
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
